December 17, 2025 (Global) – RBC Capital Markets has initiated coverage on major medical technology players Siemens Healthineers and Koninklijke Philips NV, assigning divergent outlooks based on relative strength prospects and risk profiles. RBC started Siemens Healthineers with an Outperform rating and a €55 price target, while remaining cautious on Philips due to execution and regulatory concerns.
The brokerage’s positive outlook on Siemens Healthineers reflects the belief that the company’s current valuation does not fully capture its medium-term growth potential and leading position in imaging and diagnostics markets. Analysts also highlight the possibility that strategic moves such as a potential sale of the diagnostics division could unlock further shareholder value.
In contrast, RBC assigned a Sector Perform rating to Philips with a €25 price target, citing lower sales growth potential, pressure on margins, and regulatory uncertainties that may weigh on near-term performance. The cautious view reflects execution concerns and a more conservative outlook on the company’s ability to accelerate revenue growth in a competitive global medtech environment.
Market observers say the contrasting analyst positions underscore broader investor sentiment, where stronger fundamentals and strategic clarity at Siemens Healthineers have led to greater confidence, while Philips navigates challenges that may slow its recovery trajectory. Investors will be watching upcoming earnings and strategic updates closely for additional signals on performance and risk.
Key Highlights
- RBC initiates coverage on Siemens Healthineers with an Outperform rating and €55 price target
- Positive outlook reflects undervaluation relative to growth prospects and market leadership
- RBC is cautious on Koninklijke Philips, assigning a Sector Perform rating with a €25 price target
- Concerns for Philips include slower growth, margin pressure, and execution risk
- Divergent ratings highlight differing competitive positions in the medtech sector
